Search results for " Embolism"

showing 10 items of 311 documents

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

2019

Abstract Patients with isolated pulmonary embolism (PE) have a distinct clinical profile from those with deep vein thrombosis (DVT)-associated PE, with more pulmonary conditions and atherosclerosis. These findings suggest a distinct molecular pathophysiology and the potential involvement of alternative pathways in isolated PE. To test this hypothesis, data from 532 individuals from the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism Project, a multicenter prospective cohort study with extensive biobanking, were analyzed. Targeted, high-throughput proteomics, machine learning, and bioinformatic methods were applied to contrast the acute-phase plasma proteomes of isolated PE pa…

MaleProteomeDatasets as TopicComorbidity030204 cardiovascular system & hematologyProteomicsBioinformaticsBiochemistryThrombosis and HemostasisMachine LearningPathogenesis0302 clinical medicineProtein-Arginine Deiminase Type 2Prospective StudiesProtein Interaction MapsProspective cohort study0303 health scienceseducation.field_of_studyVenous ThromboembolismHematologyMiddle AgedThrombosisPhenotypePulmonary embolismProteomeN-AcetylgalactosaminyltransferasesFemaleAdultQuantitative Trait LociImmunologyPopulationInterferon-gamma03 medical and health sciencesInterleukin-15 Receptor alpha SubunitmedicineHumansGlial Cell Line-Derived Neurotrophic FactoreducationAged030304 developmental biologybusiness.industryPulmonary SurfactantsCell BiologyAtherosclerosismedicine.diseaseOxidative StressGene Expression RegulationPulmonary EmbolismTranscriptomebusinessAcute-Phase ProteinsFollow-Up StudiesBlood
researchProduct

Successful Management of Fulminant Pulmonary Embolism Using a Novel Portable Extracorporeal Life Support System

2010

A 46-year-old man presented to the emergency room with pain in his left leg, dyspnea, and general cyanosis. During examination he collapsed and required resuscitation. Under suspicion of pulmonary embolism, a new portable "click 'n run" extracorporeal life support system (LIFEBRIDGE-B(2)T [Medizintechnik AG, Ampfing, Germany]) was implanted by the femoral vessels under resuscitation within 15 minutes of presentation. The patient was stabilized, despite severe decompensation (pH, 6.8), and could be transferred for a computed tomographic scan, which confirmed massive pulmonary embolism. Still connected to the life support system, the patient was transferred to the operating room. After a pulm…

MalePulmonary and Respiratory MedicineResuscitationmedicine.medical_specialtymedicine.medical_treatmentFulminantAdvanced Cardiac Life SupportExtracorporealPulmonary thrombectomymedicineHumansDecompensationEmergency Treatmentbusiness.industryRemission InductionOrgan dysfunctionMiddle Agedmedicine.diseaseSurgeryPulmonary embolismLife supportSurgerymedicine.symptomPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessThe Annals of Thoracic Surgery
researchProduct

Comparison of risk assessment strategies for not-high-risk pulmonary embolism

2015

We compared the prognostic performance of the 2014 European Society of Cardiology (ESC) risk stratification algorithm with the previous 2008 ESC algorithm, the Bova score and the modified FAST score (based on a positive heart-type fatty acid-binding protein (H-FABP) test, syncope and tachycardia, modified using high-sensitivity troponin T instead of H-FABP) in 388 normotensive pulmonary embolism patients included in a single-centre cohort study.Overall, 25 patients (6.4%) had an adverse 30-day outcome. Regardless of the score or algorithm used, the rate of an adverse outcome was highest in the intermediate-high-risk classes, while all patients classified as low-risk had a favourable outcome…

MalePulmonary and Respiratory MedicineTachycardiamedicine.medical_specialty030204 cardiovascular system & hematologyFatty Acid-Binding ProteinsRisk AssessmentSyncope03 medical and health sciences0302 clinical medicineRisk FactorsTachycardiaInternal medicineOdds RatiomedicineHumansProspective StudiesProspective cohort studyAgedTroponin Tbusiness.industryArea under the curveOdds ratioMiddle AgedPrognosismedicine.disease3. Good healthPulmonary embolismROC Curve030228 respiratory systemCohortCardiologyRegression AnalysisFemalemedicine.symptomPulmonary EmbolismbusinessRisk assessmentFatty Acid Binding Protein 3AlgorithmsEuropean Respiratory Journal
researchProduct

Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embol…

2015

For patients with acute symptomatic pulmonary embolism (PE), the Bova score classifies their risk for PE-related complications within 30 days after diagnosis. The original Bova score was derived from 2,874 normotensive patients with acute PE who participated in one of six prospective PE studies.We retrospectively assessed the validity of the Bova risk model in normotensive patients with acute PE diagnosed in an academic urban ED. Two clinician investigators used baseline data for the model's four prognostic variables to stratify patients into the three Bova risk stages (I-III) for 30-day PE-related complications. Intraclass correlation coefficient (ICC) and the κ statistic were used to asse…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPrognostic variableIntraclass correlationBlood PressureCritical Care and Intensive Care MedicineRisk AssessmentHeart RateInternal medicine80 and overmedicineVentricular FunctionHumansStage (cooking)AgedRetrospective StudiesAged 80 and overFramingham Risk Scorebusiness.industryTroponin IReproducibility of ResultsRetrospective cohort studyMiddle AgedPrognosismedicine.diseasePulmonary embolismSurgeryAcute Disease; Aged; Aged 80 and over; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Aged; Prognosis; Pulmonary Embolism; Reproducibility of Results; Retrospective Studies; Risk Assessment; Spain; Troponin I; Ventricular Function Right; Pulmonary and Respiratory Medicine; Critical Care and Intensive Care Medicine; Cardiology and Cardiovascular MedicineRightSpainAcute DiseaseCohortVentricular Function RightFemalePulmonary EmbolismCardiology and Cardiovascular MedicineRisk assessmentbusinessChest
researchProduct

Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism

2014

The optimal N-terminal pro-brain natriuretic peptide (NT-proBNP) cut-off value for risk stratification of pulmonary embolism remains controversial. In this study we validated and compared different proposed NT-proBNP cut-off values in 688 normotensive patients with pulmonary embolism. During the first 30 days, 28 (4.1%) patients reached the primary outcome (pulmonary embolism-related death or complications) and 29 (4.2%) patients died. Receiver operating characteristic analysis yielded an area under the curve of 0.70 (0.60-0.80) for NT-proBNP. A cut-off value of 600 pg·mL(-1) was associated with the best prognostic performance (sensitivity 86% and specificity 50%) and the highest odds ratio…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyTime Factorsmedicine.drug_classVentricular Dysfunction Right030204 cardiovascular system & hematologyLogistic regressionRisk AssessmentSensitivity and Specificity03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicineNatriuretic Peptide BrainOdds RatiomedicineNatriuretic peptideHumansProspective Studies030212 general & internal medicineProspective cohort studyAgedbusiness.industryArea under the curveReproducibility of ResultsOdds ratioMiddle AgedPrognosismedicine.diseasePeptide Fragments3. Good healthPulmonary embolismTreatment OutcomeROC CurveEchocardiographyPredictive value of testsMultivariate AnalysisCardiologyFemalePulmonary EmbolismRisk assessmentbusinessBiomarkersEuropean Respiratory Journal
researchProduct

Identification of intermediate-risk patients with acute symptomatic pulmonary embolism

2014

The identification of normotensive patients with acute pulmonary embolism (PE) at high risk of adverse PE-related clinical events (i.e. intermediate-risk group) is a major challenge. We combined individual patient data from six studies involving 2874 normotensive patients with PE. We developed a prognostic model for intermediate-risk PE based on the clinical presentation and the assessment of right ventricular dysfunction and myocardial injury. We used a composite of PE-related death, haemodynamic collapse or recurrent PE within 30 days of follow-up as the main outcome measure. The primary outcome occurred in 198 (6.9%) patients. Predictors of complications included systolic blood pressure …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyVentricular Dysfunction RightHemodynamicsBlood PressureRecurrenceRisk FactorsInternal medicineHeart rateOdds RatiomedicineHumansProspective StudiesProspective cohort studyAgedRetrospective StudiesAged 80 and overbusiness.industryHemodynamicsRetrospective cohort studyOdds ratioMiddle AgedDecision Support Systems ClinicalPrognosismedicine.diseaseSurgeryPulmonary embolismTreatment OutcomeBlood pressureCardiologyFemaleCardiomyopathiesPulmonary EmbolismbusinessComplicationEuropean Respiratory Journal
researchProduct

Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin

2015

The prognostic value of copeptin, the C-terminal fragment of the precursor protein of vasopressin which is released upon stress, and hypotension in pulmonary embolism is unknown, especially if combined with biomarkers reflecting different pathophysiological axes such as myocardial injury (high-sensitivity troponin T (hsTnT)) and stretch (N-terminal pro-brain natriuretic peptide (NT-proBNP)).We prospectively studied 268 normotensive pulmonary embolism patients included in a single-centre cohort study.Patients with an adverse 30-day outcome (5.6%) had higher copeptin levels than patients with a favourable course (median (interquartile range) 51.8 (21.6–90.8) versus 13.2 (5.9–39.3) pmol·L−1; p…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classVentricular Dysfunction Right030204 cardiovascular system & hematologyRisk AssessmentCohort Studies03 medical and health sciencesCatecholamines0302 clinical medicineCopeptinTroponin TInterquartile rangeInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansProspective StudiesProspective cohort studyAgedTroponin Tbusiness.industryGlycopeptidesMiddle AgedPrognosismedicine.diseaseRespiration ArtificialCardiopulmonary ResuscitationPeptide Fragments3. Good healthPulmonary embolism030228 respiratory systemCardiologyFemalePulmonary EmbolismRisk assessmentbusinessBiomarkersCohort studyEuropean Respiratory Journal
researchProduct

Anticoagulant drugs in noncompaction: A mandatory therapy?

2008

BACKGROUND: Noncompaction of left ventricular myocardium is a rare congenital cardiomyopathy resulting from an incomplete myocardial morphogenesis that leads to the persistence of the embryonic myocardium. This condition is characterized by a thin compacted epicardial and an extremely thickened endocardial layer with prominent trabeculations and deep intertrabecular recesses. It is not clear, in noncompaction of myocardium, whether intertrabecular recesses could be responsible for thrombi formation and thromboembolic complications. METHODS: The prevalence of stroke and echocardiographic finding of thrombus was evaluated in a continuous series of 229 patients (men and women) affected by nonc…

MaleRegistrieTime FactorsEmbolismAdministration OralHeart VentricleRisk FactorsRegistriesStrokeIschemic strokeAnticoagulantCongenital cardiomyopathyGeneral MedicineMiddle AgedStrokeAnticoagulant drugsCardiologycardiovascular systemFemaleAnticoagulant drugs noncompactionCardiomyopathiesCardiology and Cardiovascular MedicineHumanAdultHeart Defects Congenitalmedicine.medical_specialtyStroke etiologyTime Factormedicine.drug_classIsolated left ventricular noncompactionHeart Ventriclesanticoagulant; embolism; ischemic stroke; Isolated left ventricular noncompactionInternal medicineThromboembolismmedicineHumanscardiovascular diseasesThrombusNoncompactionCardiomyopathiebusiness.industryRisk FactorAnticoagulantAnticoagulantsInfantmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEmbolismIschemic strokeThrombuLeft ventricular myocardiumbusiness
researchProduct

Impact of pulmonary embolism on in-hospital mortality of patients with ischemic stroke

2020

Pulmonary embolism (PE) is a frequent complication in immobile stroke patients and an important cause of death in stroke patients. We aimed to investigate predictors of PE and the impact of PE on survival of ischemic stroke patients.Patients were selected by screening the German nationwide inpatient sample (2005-2017) for ischemic stroke (ICD-code I63) and stratified for occurrence of PE (ICD-code I26). Impact of PE on mortality and predictors for PE in ischemic stroke patients were analysed.Overall, 2,914,546 patients were hospitalized due to ischemic stroke (50.5% females; 69.3% aged ≥70 years) in Germany 2005-2017. Among these, 0.4% had PE and 7.2% died during hospitalization. In-hospita…

MaleResuscitationmedicine.medical_specialtymedicine.medical_treatmentBrain Ischemia03 medical and health sciences0302 clinical medicineGermanyInternal medicineHumansMedicineHospital Mortalitycardiovascular diseases030212 general & internal medicineAgedIschemic StrokeCause of deathIn hospital mortalitybusiness.industryMortality rateThrombolysismedicine.diseasePulmonary embolismStrokeNeurologyIschemic strokeCardiologyFemaleNeurology (clinical)Pulmonary EmbolismbusinessComplication030217 neurology & neurosurgeryJournal of the Neurological Sciences
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct